Patent protected and proprietary compositions that leverage innovations in particle engineering and continuous processes based on spray drying.
Proprietary spray dry manufacturing process eliminates hydrolysis of drug product.
Amorphous Solid Dispersions (ASD) produced via spray drying exhibit enhanced reconstitution, dissolution and bioavailability properties compared to conventional powder forms.
The continuous nature of spray dried enables the production of otherwise unstable or energetic compounds.
By utilizing the FDA 505b2 regulatory pathway, we seek a rapid development and regulatory review of significantly optimized forms of commercialized products.
© Exinda Therapeutics LLC, 2024. All Rights Reserved.